Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer

16Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Increased insulin-like growth factor (IGF) signalling has been observed in breast cancer, including endocrine-responsive cancers, and has been linked to disease progression and recurrence. In particular, IGF-1 has the ability to induce and promote lymphangiogenesis through the induction of vascular endothelial growth factor C (VEGFC). In the present study, we analyzed serum and tumour samples from 60 patients with endocrine-positive breast cancer to determine the expression and the possible relationship of circulating IGF-1, IGF binding protein 3 (IGFBP3), and VEGFC with the presence of lymphatic metastasis and other immunohistochemical parameters. The analysis revealed a clear and significant correlation between high basal levels of IGF-1, IGFBP3, and VEGFC and lymph node metastasis in endocrine-responsive breast cancer. In addition, expression of those molecules was significantly higher in breast cancer patients than in healthy control subjects. Those findings may enable more accurate prediction of prognosis in patients with breast cancer. © 2013 Multimed Inc.

Author supplied keywords

Cite

CITATION STYLE

APA

Morgillo, F., De Vita, F., Antoniol, G., Orditura, M., Auriem, P. P., Diadema, M. R., … Iovino, F. (2013). Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer. Current Oncology, 20(4). https://doi.org/10.3747/co.20.1380

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free